Hip Dysplasia in Dogs: Welfare Management from Diagnosis to End of Life

Hip dysplasia is a heritable orthopaedic condition causing lifelong pain in affected dogs, requiring proactive management across all life stages.

Key Facts

Canine hip dysplasia is caused by abnormal development of the hip joint leading to laxity and secondary osteoarthritis.
Large and giant breeds including German Shepherds, Labradors, and Golden Retrievers show highest prevalence.
Symptoms range from exercise intolerance and bunny hopping gait in puppies to severe lameness in adults.
Radiographic screening programmes including OFA and BVA/KC Hip Scheme enable informed breeding selection.
Surgical options include juvenile pubic symphysiodesis, triple pelvic osteotomy, and total hip replacement.
Medical management combines weight control, physiotherapy, NSAIDs, and joint supplements.
Quality of life can be maintained for many years with appropriate management even in severely affected dogs.

Welfare Considerations

Hip dysplasia welfare management spans the dog entire life, from breeding selection to end-of-life decisions. Breeders who screen breeding stock and select against dysplasia reduce population-level suffering. Owners who manage weight, provide appropriate exercise, and use evidence-based pain management maximise quality of life for affected dogs. The welfare cost of hip dysplasia is significant: chronic joint pain affects gait, exercise tolerance, sleep quality, and overall mental state. Surgical options can dramatically improve welfare for selected cases, particularly when performed at optimal ages. End-of-life decisions must honestly assess when pain management no longer provides adequate quality of life.

What You Can Do

Choose breeders who screen all breeding stock through recognised hip scoring schemes.
Manage body weight carefully in dysplastic dogs to reduce joint loading.
Implement physiotherapy alongside medical management for best welfare outcomes.
Discuss surgical options with an orthopaedic specialist for dogs with severe dysplasia.
Use validated quality of life tools to guide end-of-life timing decisions objectively.